Expedia, Inc. Names New Presidents of Worldwide Partner

Expedia, Inc. (Nasdaq: EXPE), the world's leading online travel company, today appointed long-time Expedia veterans Dhiren Fonseca and Gary Fritz to lead its global Partner Services Group (PSG). Get full story at http://wallstreetnewsalert.com/fullstory.php?id=951

read more | digg story

Wall Street is narrowly mixed in early trading

Stocks are narrowly mixed in early trading after the government issued better-than-expected reports on the housing market and inflation.The...Full story at www.wallstreetnewsalert.com

read more | digg story

White House wants limits on $30 billion bound for AIG

The Obama administration says it's trying to put strict limits on the next $30 billion installment in taxpayers' money for insurance giant AIG amid questions...Full story at www.wallstreetnewsalert.com

read more | digg story

Dell hopes PCs can't be too rich or too thin but just right

The way it came on the scene, it could have been a rare perfume or a designer handbag, undaunted by the roiling economy.The first rumors...Full story at www.wallstreetnewsalert.com

read more | digg story

Housing starts surge; wholesale prices edge up

Housing construction posted a surprisingly large increase in February, bolstered by strength in all parts of the country except the West.The...Full story at www.wallstreetnewsalert.com

read more | digg story

Oncolin Therapeutics announces it has Reached an Agreement on its Subsidiary, Intertech Bio

There is important breaking news coming from Oncolin Therapeutics (OTCBB: OCOL) and investors are going to watch this one closely. Yesterday after the markets closed, the company issued a press release announcing that it has reached a tentative agreement with Intertech Bio's founding scientist and consultants.

Intertech Bio has been a wholly owned subsidiary of the company that focused on the discovery, development and commercialization of novel selective anticancer therapies. The board has determined that due to the current economic conditions it is not able to meet the obligations of an early stage biotech company such as Intertech Bio.

This decision has lead the company to successfully negotiate with the scientist and consultants to accept approximately 75% of the outstanding stock of Intertech Bio in exchange for the assumption of certain liabilities and future obligations associated with the ongoing operations of Intertech Bio. Oncolin will retain an approximate 25% interest in Intertech Bio when finalized and will not be responsible for future expenses associated with Intertech Bio. This move will also allow Intertech Bio to be classified as a private entity and pursue grants and also traditional venture capital of which it has already identified several potential sources of capital. Oncolin will reserve the right to participate in future investments for Intertech Bio.

Read More

Penny Stocks Alert: Striker Oil & Gas Production increases

With 2008 financial numbers announced this week, and additional news just released, Striker Oil & Gas, Inc. (OTCBB: SOIS) should have investors monitoring this stock. Yesterday after the markets closed, the company, an upstream U.S. oil and gas company, announces that...

read more | digg story